Otsuka Holdings Co Ltd is a Japan-based company mainly engaged in medical, nutraceutical, consumer and other business activities in Japan and overseas. The Company operates in four business segments. The Medical Business segment produces and sells therapeutic drugs and infusions. The Nutraceutical segment produces and sells functional beverages, quasi-drugs and nutritional supplements. The Consumer Products segment produces and sells mineral water, beverages and food products. The Others segment manufactures paper containers, manufactures synthetic resin molded products, stores products, provides storage space, and produces and sells chemicals and liquid crystal evaluation equipment, spectroscopic analysis equipment, and other products.

Employees

35,338

Sector

Pharmaceuticals

Calendar

07-31 - Q2 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
25-07-17	6,661.00 ¥	+1.12%	967,500
25-07-16	6,587.00 ¥	0.00%	909,900
25-07-15	6,587.00 ¥	-0.50%	834,700
25-07-14	6,620.00 ¥	-1.05%	859,900
25-07-11	6,690.00 ¥	+1.36%	1,365,200

Delayed Quote Japan Exchange, July 17, 2025 at 02:30 am

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6,587.00JPY

Average target price

9,050.00JPY

Spread / Average Target

+37.39%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 02:30:00 2025-07-17 EDT			5-day change	1st Jan Change
6,661.00 ^JPY	+1.12%		+0.92%	-22.55%

06:26am	Cantargia Sells CAN10 Program to Otsuka for Over $600 Million	FW
07-16	FDA staff raises efficacy concerns for Otsuka's PTSD combination treatment	RE

Capitalization	3,478B 23.6B 20.22B 18.81B 17.54B 32.32B 2,025B 36.07B 228B 85.97B 950B 88.52B 86.69B	P/E ratio 2025 *	12.2x	P/E ratio 2026 *	13.3x
Enterprise value	3,099B 21.03B 18.01B 16.76B 15.62B 28.8B 1,804B 32.13B 203B 76.6B 846B 78.87B 77.24B	EV / Sales 2025 *	1.28x	EV / Sales 2026 *	1.23x
Free-Float	81.22%	Yield 2025 *	1.86%	Yield 2026 *	1.87%

Cantargia Sells CAN10 Program to Otsuka for Over $600 Million	06:26am	FW
FDA staff raises efficacy concerns for Otsuka's PTSD combination treatment	07-16	RE
Fda staff raises efficacy concerns for Otsuka's PTSD combination drug	07-16	RE
Jefferies Adjusts Otsuka Holdings' Price Target to 9,700 Yen From 9,500 Yen, Keeps at Buy	06-11	MT
Nikkei index jumps as chip stocks rally ahead of Sino-US talks	06-09	RE
Japan's Nikkei jumps as chip stocks rally ahead of Sino-US talks	06-08	RE
Otsuka Presents IgAN Drug Study Results at EU Medical Conference	06-08	MT
Otsuka's kidney disease therapy trial results heat up battle with rival Vera	06-06	RE
Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)	06-06	RE
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. Present Results from a Pre-specified Interim Analysis of the Phase 3 Vision Study Evaluating Sibeprenlimab, for the Treatment of Immunoglobulin A Nephropathy	06-06	CI
Otsuka's kidney disease drug shows over 50% reduction in protein in urine	06-06	RE
Vera shares skyrocket as kidney disease drug succeeds in late-stage trial	06-02	RE
Vera shares skyrocket as kidney disease drug succeeds in late-stage trial	06-02	RE

Jefferies Adjusts Otsuka Holdings' Price Target to 9,700 Yen From 9,500 Yen, Keeps at Buy	06-11	MT
Jefferies Adjusts Otsuka Holdings' Price Target to 9,500 Yen From 10,500 Yen, Keeps at Buy	04-29	MT
Jefferies Adjusts Otsuka Holdings' Price Target to 10,500 Yen From 9,700 Yen, Keeps at Buy	24-10-18	MT
Jefferies Adjusts Otsuka Holdings' Price Target to 9,700 Yen From 9,300 Yen, Keeps at Buy	24-08-27	MT
Jefferies Adjusts Otsuka Holdings' Price Target to 9,300 Yen From 8,600 Yen, Keeps at Buy	24-08-19	MT

Otsuka Holdings Co., Ltd. Stock

Equities

4578

JP3188220002

Pharmaceuticals

Valuation: Otsuka Holdings Co., Ltd.

Chart: Otsuka Holdings Co., Ltd.

Latest news: Otsuka Holdings Co., Ltd.

Last Transcript: Otsuka Holdings Co., Ltd.

Analysts' recommendations: Otsuka Holdings Co., Ltd.

Press Releases: Otsuka Holdings Co., Ltd.

News in other languages: Otsuka Holdings Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Otsuka Holdings Co., Ltd.

ETFs: Otsuka Holdings Co., Ltd.

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Otsuka : Message from Tatsuo Higuchi, President and Representative Director, CEO	24-10-31	PU
Otsuka : Message from Makoto Inoue, Representative Director, COO	24-10-31	PU
Otsuka Group Selected for CDP Climate Change a List for a Second Consecutive Year	24-02-08	AQ
Otsuka Holdings Co., Ltd. - Donations to Support Relief Efforts Following the Noto Peninsula Earthquake	24-01-10	AQ
Recor Medical Announces U.S. Launch and First Commercial Cases of Paradise Ultrasound Renal Denervation Therapy	23-11-10	BU

Trump baissera-t-il le pouce ?	03:53am
Bourse : Belles publications chez Publicis et Legrand, Rheimetall en pourparlers et TSMC explose les compteurs	02:29am
Borsa di Italia: a caccia del naturale	24-08-01
Bolsa de Madrid: A la caza de lo natural	24-08-01
Chassez le naturel…	24-08-01

1 day	+1.12%
1 week	+0.92%
Current month	-6.85%
1 month	-7.37%
3 months	-2.04%
6 months	-16.34%
Current year	-22.55%

1 week	6,540	6,763
1 month	6,540	7,160
Current year	6,465	8,631
1 year	6,465	9,669
3 years	3,827	9,669
5 years	3,827	9,669
10 years	3,224	9,669

Manager	Title	Age	Since
Makoto Inoue CEO	Chief Executive Officer	66	2024-12-31
Yuko Makino DFI	Director of Finance/CFO	63	2018-02-28
Masanori Udagawa CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Tatsuo Higuchi BRD	Director/Board Member	75	2008-07-07
Ichiro Otsuka CHM	Chairman	60	2015-02-28
Masayuki Kobayashi BRD	Director/Board Member	59	2017-03-29

Name	Weight	AuM	1st Jan change
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY	6.36%	28 M€	-7.51%	-
NEXT FUNDS SOLACTIVE JAPAN ESG CORE INDEX ETF - JPY	0.86%	4 M€	-30.99%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
OTSUKA HOLDINGS CO., LTD.	+1.12%	+0.92%	-8.99%	+36.97%	23.6B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.14%	+2.46%	+6.85%	+92.95%	47.56B
SANDOZ GROUP AG	-0.36%	+0.42%	+30.62%	-	24.3B
CIPLA LIMITED	+0.45%	+0.31%	-1.61%	+53.24%	13.89B
ZYDUS LIFESCIENCES LIMITED	+1.43%	+1.01%	-17.11%	+174.32%	11.36B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+4.36%	+6.69%	+72.69%	+92.51%	7.5B
GLENMARK PHARMACEUTICALS LIMITED	+0.99%	+16.95%	+57.55%	+483.75%	7.25B
KRKA, D. D.	-0.25%	+1.79%	+33.11%	+100.60%	7.11B
THE MEDICINES COMPANY	-.--%	+0.14%	-	-	6.79B
STADA ARZNEIMITTEL	-.--%	-1.95%	-	-	5.73B
Average	+0.79%	+2.77%	+21.64%	+147.76%	15.51B
Weighted average by Cap.	+0.55%	+1.76%	+12.90%	+109.32%

	2025 *	2026 *
Net sales	2,414B 16.38B 14.03B 13.06B 12.17B 22.43B 1,405B 25.03B 158B 59.66B 659B 61.42B 60.15B	2,420B 16.42B 14.06B 13.09B 12.2B 22.49B 1,409B 25.09B 159B 59.81B 661B 61.59B 60.31B
Net income	292B 1.98B 1.7B 1.58B 1.47B 2.71B 170B 3.03B 19.15B 7.21B 79.68B 7.43B 7.27B	265B 1.8B 1.54B 1.43B 1.33B 2.46B 154B 2.74B 17.37B 6.54B 72.26B 6.73B 6.6B
Net Debt	-379B -2.57B -2.2B -2.05B -1.91B -3.52B -221B -3.93B -24.89B -9.37B -104B -9.65B -9.45B	-492B -3.34B -2.86B -2.66B -2.48B -4.57B -286B -5.1B -32.29B -12.16B -134B -12.52B -12.26B